Vivacitas Oncology Presents its New Neuro-Oncology Advisor, Dr. Andrew Lassman MD, MS, FAAN
WALNUT CREEK, CALIFORNIA, US, December 15, 2021 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to– treat cancers, is pleased to announce the addition of Dr. Andrew Lassman to their Scientific Advisory Board. Dr. Andrew Lassman With over 20 years of experience in translational neuro-oncology research, Dr. Lassman is board certified in […]
Vivacitas Oncology, Inc. and Image Analysis Group to Present on AR-67 Clinical Response Evaluation at the Society for Neuro-oncology Annual Conference
Walnut Creek, CA, USA, and London, UK, November 18, 2021, Vivacitas Oncology, a privately-held oncology company focused on tough–to–treat cancers, and Image Analysis Group (IAG), a premier image analysis company and developer of the proprietary Artificial Intelligence (AI)-assisted DynamikaTM platform will present a poster at this year’s annual Society of Neuro-Oncology (SNO) conference November 18-21, 2021 […]
Vivacitas Oncology, Inc. and Image Analysis Group to Present on AR-67 Clinical Response Evaluation at the Society for Neuro-oncology Annual Conference
Walnut Creek, CA, USA, and London, UK, November 18, 2021, Vivacitas Oncology, a privately-held oncology company focused on tough–to–treat cancers, and Image Analysis Group (IAG), a premier image analysis company and developer of the proprietary Artificial Intelligence (AI)-assisted Dynamika™ platform will present a poster at this year’s annual Society of Neuro-Oncology (SNO) conference November 18-21, 2021 in Boston, MA.
DSS Continues to Grow its Healthcare Segment through $1M Investment in Vivacitas Oncology
ROCHESTER, N.Y., August 2, 2021 (GLOBE NEWSWIRE) — Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets, announced today that its subsidiary, DSS Biomedical International, Inc. (“DSS Biomedical”), completed a $1 million equity investment in Vivacitas Oncology, Inc. (“Vivacitas”), a clinical-stage company focused on difficult-to-treat cancers.
Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients
[WALNUT CREEK, CALIFORNIA, US AND LONDON, UK, May 3, 2021] – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a clinical stage biopharmaceutical company focused on tough to treat cancers, and Image Analysis Group (“IAG”), a leading global medical imaging company, are collaborating to apply Artificial Intelligence (AI) technology and advanced imaging strategies to further the development of AR-67, a third generation Camptothecin, in patients with recurrent glioblastoma multiforme (reGBM).
DSS Expands its Healthcare Segment through Investment in Vivacitas Oncology
ROCHESTER, N.Y., April 08, 2021 (GLOBE NEWSWIRE) — Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced DSS Biomedical International, Inc. (“DSS Biomedical”), a subsidiary of Impact BioMedical, Inc., a wholly owned subsidiary of the Company, completed an equity investment in Vivacitas Oncology, Inc. (“Vivacitas”), a clinical-stage company focused on difficult to treat cancers.